Indian Drug Makers Seek Ban On Patent Evergreening Under New Regime

Law360, New York (November 28, 2004, 12:00 AM EST) -- Indian drug makers have urged the government to stamp out patent evergreening by banning the patenting of “trivial changes” to “essentially similar” molecules, as the industry braces for the introduction of product patents in January.

The Indian Pharmaceutical Alliance (IPA), which represents many of the country’s generic drug companies, has written a letter to finance minister P. Chidambaram seeking his support to preclude various new "forms" of already patented molecules from patenting, according to the Financial Express.

Allowing such patents would exceed India’s obligations under the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.